Stefan A. Laufer

发表

Fine-tuned PEGylation of chitosan to maintain optimal siRNA-nanoplex bioactivity.

B. Schlosshauer, Andra Guţoaia, Liane Schuster, 2016, Carbohydrate polymers.

Improved Multigram Route to a Tricyclic Key Intermediate for Dibenzosuberone-Based p38 Inhibitors via an Optimized Early-Stage Heck Coupling

Stefan A. Laufer, M. Forster, Heike K. Wentsch-Teltschik, 2021, Organic Process Research & Development.

Discrepancy in interactions and conformational dynamics of pregnane X receptor (PXR) bound to an agonist and a novel competitive antagonist

T. Kronenberger, Stefan A. Laufer, O. Burk, 2022, Computational and structural biotechnology journal.

Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure–Activity Relationships, Antiviral Activity, and X-ray Structure Determination

Yechun Xu, A. Poso, M. Gütschow, 2022, Journal of medicinal chemistry.

Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells.

S. Knapp, D. Schollmeyer, Stefan A. Laufer, 2022, ACS pharmacology & translational science.

Are MAP Kinases Drug Targets? Yes, but Difficult Ones

Simona Margutti, Stefan A. Laufer, 2007, ChemMedChem.

Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation.

A. Poso, Stefan A. Laufer, A. Kaczor, 2022, Journal of medicinal chemistry.

Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448).

Daniel A. Urul, M. Eck, P. Hershberger, 2022, ACS medicinal chemistry letters.

Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX.

O. Werz, J. Bauer, Stefan A. Laufer, 2012, Journal of medicinal chemistry.

United States Patent

Stefan A. Laufer, C. Tsang, 2007 .

Substituted Isoxazoles as Potent Inhibitors of p38 MAP Kinase

Simona Margutti, Stefan A. Laufer, Martin Fritz, 2006, ChemMedChem.

Chemical Probes for Understudied Kinases: Challenges and Opportunities.

J. Elkins, W. Zuercher, Stefan A. Laufer, 2021, Journal of medicinal chemistry.

Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19

T. Kronenberger, Hang Xie, S. Pöhlmann, 2023, Pharmaceuticals.

Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.

Anna M. Schmoker, S. Knapp, P. Jänne, 2021, Journal of medicinal chemistry.

Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase.

D. Schollmeyer, Stefan A. Laufer, S. Fischer, 2012, Journal of medicinal chemistry.

Synthesis and Biological Testing of N‐Aminoimidazole‐Based p38α MAP Kinase Inhibitors

Stefan A. Laufer, C. Bracht, W. Albrecht, 2010, ChemMedChem.

Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer.

L. Zender, T. Kronenberger, P. Witt-Enderby, 2022, Journal of medicinal chemistry.

Decisive role of water and protein dynamics in residence time of p38α MAP kinase inhibitors

U. Rothbauer, P. Kaiser, Stefan A. Laufer, 2022, Nature Communications.

Decisive role of water and protein dynamics in residence time of p38α MAP kinase inhibitors

U. Rothbauer, P. Kaiser, Stefan A. Laufer, 2022, Nature communications.

MKK4 Inhibitors—Recent Development Status and Therapeutic Potential

Stefan A. Laufer, Pascal Sander, Leon Katzengruber, 2023, International journal of molecular sciences.

Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors.

L. Zender, Stefan A. Laufer, W. Albrecht, 2022, European journal of medicinal chemistry.

Novel Hinge‐Binding Motifs for Janus Kinase 3 Inhibitors: A Comprehensive Structure–Activity Relationship Study on Tofacitinib Bioisosteres

S. Laufer, Stefan A. Laufer, M. Gehringer, 2014, ChemMedChem.

Design and Synthesis of Tricyclic JAK3 Inhibitors with Picomolar Affinities as Novel Molecular Probes

S. Laufer, Stefan A. Laufer, M. Gehringer, 2014, ChemMedChem.

COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease

T. Kronenberger, Stefan A. Laufer, Thanigaimalai Pillaiyar, 2023, Drug Discovery Today.

Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands

T. Kronenberger, Stefan A. Laufer, D. Zlotos, 2022, Pharmaceutics.

Targeting SARS-CoV-2 Main Protease (MPro) with Kinase Inhibitors: A Promising Approach for Discovering Antiviral and Anti-inflammatory Molecules against SARS-CoV-2

Stefan A. Laufer, M. Goettert, L. F. Saraiva Macedo Timmers, 2023, J. Chem. Inf. Model..

Selective Inhibitors of Janus Kinase 3 Modify Responses to Lipopolysaccharides by Increasing the Interleukin-10-to-Tumor Necrosis Factor α Ratio.

Stefan A. Laufer, M. Burnet, Julia Laux, 2023, ACS pharmacology & translational science.

A patent review of MAPK inhibitors (2018 – present)

Stefan A. Laufer, Valentin Wydra, Raphael B Ditzinger, 2023, Expert opinion on therapeutic patents.

Novel Hinge‐Binding Motifs for Janus Kinase 3 Inhibitors: A Comprehensive Structure–Activity Relationship Study on Tofacitinib Bioisosteres

Stefan A. Laufer, M. Gehringer, S. Bauer, 2014, ChemMedChem.

Pharmacokinetics of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor

Stefan A. Laufer, C. Gleiter, W. Albrecht, 2007 .

Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors.

M. Eck, Stefan A. Laufer, D. Heppner, 2023, Methods in enzymology.

The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma

T. Kronenberger, Stefan A. Laufer, K. Ruhm, 2024, Nature communications.

Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors.

Stefan A. Laufer, Florian Wittlinger, B. Ogboo, 2023, Journal of medicinal chemistry.

Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SNAr Electrophiles.

Stefan A. Laufer, M. Gehringer, D. Dauch, 2024, Journal of medicinal chemistry.

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers

S. Mainardi, Stefan A. Laufer, A. Bosma, 2024, Proceedings of the National Academy of Sciences of the United States of America.

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

Stefan A. Laufer, T. Beyett, Tatiana Shaurova, 2024, Communications chemistry.

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

Stefan A. Laufer, T. Beyett, Tatiana Shaurova, 2023, Research square.

Development of Ligands for the Super Conserved Orphan G Protein-Coupled Receptor GPR27 with Improved Efficacy and Potency.

T. Kronenberger, Stefan A. Laufer, Aenne-Dorothea Liebing, 2023, Journal of medicinal chemistry.

The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation

Stéphanie M. Guéret, A. Vulpetti, G. Sbardella, 2023, ChemMedChem.